APA (7th ed.) Citation

Hsu, J., Chong, C., Goon, L., Balayan, J., Wu, S., Johnson, E., . . . Yu, P. (2020). 33 Poster Discussion - XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile. European Journal of Cancer, 138, S16. https://doi.org/10.1016/S0959-8049(20)31107-2

Chicago Style (17th ed.) Citation

Hsu, J., et al. "33 Poster Discussion - XL092, a Multi-targeted Inhibitor of MET, VEGFR2, AXL and MER with an Optimized Pharmacokinetic Profile." European Journal of Cancer 138 (2020): S16. https://doi.org/10.1016/S0959-8049(20)31107-2.

MLA (9th ed.) Citation

Hsu, J., et al. "33 Poster Discussion - XL092, a Multi-targeted Inhibitor of MET, VEGFR2, AXL and MER with an Optimized Pharmacokinetic Profile." European Journal of Cancer, vol. 138, 2020, p. S16, https://doi.org/10.1016/S0959-8049(20)31107-2.